PARSIPPANY, N.J.--(BUSINESS WIRE)--The Medicines Company will present new clinical data on ABP-700 – a novel intravenous (IV) anesthetic under development for general anesthesia and procedural sedation – at ANESTHESIOLOGY 2015, the annual congress of the American Society of Anesthesiologists, October 24-28 in San Diego. ABP-700 has the potential to advance the safety and efficiency of surgical and procedural care.
More than 315 million surgeries are performed worldwide each year1, yet there have been few innovations in anesthetics since the introduction of propofol in 1987. “Innovations in anesthesia have not kept pace with overall demand for surgery or the shift to less invasive, out-patient procedures requiring fast-acting and quickly reversible agents with improved safety profiles,” said Clive A. Meanwell, MD, PhD, Chief Executive Officer of The Medicines Company. “We are encouraged by promising early results with ABP-700 demonstrating the dramatic potential of this compound to address shortcomings of currently available drugs including propofol.”
Help employers find you! Check out all the jobs and post your resume.
